Skip to main content
. 2021 May 7;2(5):100267. doi: 10.1016/j.xcrm.2021.100267

Figure 7.

Figure 7

Combination assessments of dasatinib and preclinical MEK inhibitors, and the effect of the cabozantinib-cobimetinib combination

(A–E): Dose response to MEK inhibitors is presented both as single agent (red) and in the presence of dasatinib (green). The best-fit line represents the variable slope (log(inhibitor) versus response). (A) PD325901, (B) CI-1040, (C) TAK733, (D) BIX02189, and (E) PD318088 (n = 5 inhibitors).

(F) Dose-response curves of cell viability of human NCCRCC cell lines ACHN and SN12C to varying doses of cabozantinib and cobimetinib after 72 h of exposure.

(G) Calculated median effect drug synergy CI scores (CalcuSyn) across cabozantinib and cobimetinib combinations. Horizontal dashed line indicates a CI = 1, where points below the line indicate synergy and points above indicate antagonism.